Evotec partners P2X7 antagonist programme, EVT 401, to a top tier global animal health company

8/11/2011, 6:52 AM (Source: GlobeNewswire)
Evotec AG /
Evotec partners P2X7 antagonist programme, EVT 401, to a top tier global animal
health company
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.

* Exclusive license granted to major animal health company for development of
Evotec proprietary compound

Hamburg, Germany - 11 August 2011: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX) today announced that it has entered into a world-wide license and
collaboration agreement with a top tier animal health company that intends to
develop the proprietary Evotec compound EVT401, a selective, small molecule P2X7
antagonist, in the companion animal market.
Evotec is entitled to receive a technology- transfer payment, development and
commercial milestone payments, and tiered royalties on net sales. Evotec retains
all rights to the programme for human therapeutic use.
Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "We are very
pleased to be partnering with a company that has proven capabilities for
developing drug candidates for animal indications. This deal not only gives us
additional product value, but also nicely proves the strength of our medicinal
chemistry approach. We look forward to closely collaborate with this top animal
health company to make this product development a success."
Financial details related to the agreement are not being disclosed.

About EVT401

The P2X7 receptor is an ATP-gated ion channel primarily expressed on cells of
the immune system and is thought to play an important role in inflammatory
processes through the regulation of a number of proinflammatory cytokines such
as IL-1ß. P2X7 receptor antagonism may therefore provide a novel approach for
the treatment of inflammatory conditions.

Contact Evotec AG:
Dr Werner Lanthaler, Chief Executive Officer, Phone:

Forward-Looking Statements - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent the
judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a variety of
risks and uncertainties, many of which are beyond our control, and which could
cause actual results to differ materially from those contemplated in these
forward-looking statements. We expressly disclaim any obligation or undertaking
to release publicly any updates or revisions to any such statements to reflect
any change in our expectations or any change in events, conditions or
circumstances on which any such statement is based.

--- End of Message ---

Evotec AG
Schnackenburgallee 114 Hamburg Germany

WKN: 566480;ISIN: DE0005664809;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;

Pdf of PressRelease:

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Evotec AG via Thomson Reuters ONE

Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.